The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.
More Latest News
March 31, 2017
Upcoming License Renewals With license renewal deadlines looming, nursing professionals are advised to circle crucial upcoming dates on their calendars. All of them fall during the Spring and Summer months: Registered Nurses (RNs) and Advanced Registered Nurse Practitioners (ARNPs) have … Continue reading
March 30, 2017
The National Council of State Boards of Nursing (NCSBN) has released a Special Issue of their Leader to Leader Publication regarding the Enhanced Nurse Licensure Compact (eNLC). This issue contains articles such as: What Educators Need to Know About the … Continue reading